<DOC>
	<DOCNO>NCT02684357</DOCNO>
	<brief_summary>This randomize double blind , double dummy , placebo active comparator control , parallel design study perform assess safety efficacy BI 655066 support registration treatment moderate severe chronic plaque psoriasis adult patient .</brief_summary>
	<brief_title>BI 655066 Compared Placebo &amp; Active Comparator ( Ustekinumab ) Patients With Moderate Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>Inclusion criterion : Male female patient . Women childbearing potential* must ready able use highly effective method birth control per ICH M3 ( R2 ) result low failure rate le 1 % per year use consistently correctly . A list contraception method meet criterion provide patient information . *Women childbearing potential define : experienced menarche postmenopausal ( 12 month menses without alternative medical cause ) permanently sterilize ( e.g. , tubal occlusion , hysterectomy , bilateral oophorectomy bilateral salpingectomy ) . Age &gt; = 18 year screen Have diagnosis chronic plaque psoriasis ( without psoriatic arthritis ) least 6 month first administration study drug.Duration diagnosis may report patient , Have stable moderate severe chronic plaque psoriasis without psoriatic arthritis Screening Baseline ( Randomization ) : 1 . Have involve body surface area ( BSA ) &gt; = 10 % 2 . Have Psoriasis Area Severity Index ( PASI ) score &gt; = 12 3 . Have static Physician Global Assessment ( sPGA ) score &gt; = 3 . Must candidate systemic therapy phototherapy psoriasis treatment , assessed investigator Must candidate treatment Stelara® ( ustekinumab ) accord local label . Signed date write informed consent prior admission study accordance GCP local legislation Exclusion criterion : Patients : 1. nonplaque form psoriasis ( include guttate , erythrodermic , pustular ) , 2. current druginduced psoriasis ( include exacerbation psoriasis beta blocker , calcium channel blocker , lithium ) , 3. active ongoing inflammatory disease psoriasis psoriatic arthritis might confound trial evaluation accord investigator 's judgment , Previous exposure BI 655066 , Currently enrol another investigational study le 30 day ( screen ) since complete another investigational study ( participation observational study permit ) , Previous exposure ustekinumab ( Stelara® ) , Use restrict medication , drug consider likely interfere safe conduct study , Major surgery perform within 12 week prior randomization plan within 12 month screen ( e.g . hip replacement , aneurysm removal , stomach ligation ) , Known chronic relevant acute infection include active tuberculosis , HIV viral hepatitis ; QuantiFERON® TB test PPD skin test perform accord local labelling comparator product . If result positive , patient may participate study work ( accord local practice/guidelines ) establish conclusively patient evidence active tuberculosis . If presence latent tuberculosis establish , treatment initiate maintain accord local country guideline , Any document active suspected malignancy history malignancy within 5 year prior screen , except appropriately treat basal squamous cell carcinoma skin situ carcinoma uterine cervix , Evidence current previous disease , medical condition ( include chronic alcohol drug abuse ) psoriasis , surgical procedure ( i.e. , organ transplant ) , medical examination finding ( include vital sign ECG ) , laboratory value screen visit outside reference range opinion investigator , clinically significant would make study participant unreliable adhere protocol complete trial , compromise safety patient , compromise quality data , History allergy/hypersensitivity systemically administer biologic agent excipients , Women pregnant , nursing , plan become pregnant trial , Previous enrolment trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>ABBV-066</keyword>
	<keyword>BI 655066</keyword>
	<keyword>risankizumab</keyword>
</DOC>